Skip to main content
Download PDF

Characterization of genes related to the efflux pump and porin in multidrug-resistant Escherichia coli strains isolated from patients with COVID-19 after secondary infection

BMC Microbiology volume 24, Article number: 122 (2024) Cite this article

Abstract

Background

Escherichia coli (E. coli) is a multidrug resistant opportunistic pathogen that can cause secondary bacterial infections in patients with COVID-19. This study aimed to determine the antimicrobial resistance profile of E. coli as a secondary bacterial infection in patients with COVID-19 and to assess the prevalence and characterization of genes related to efflux pumps and porin.

Methods

A total of 50 nonduplicate E. coli isolates were collected as secondary bacterial infections in COVID-19 patients. The isolates were cultured from sputum samples. Confirmation and antibiotic susceptibility testing were conducted by Vitek 2. PCR was used to assess the prevalence of the efflux pump and porin-related genes in the isolates. The phenotypic and genotypic evolution of antibiotic resistance genes related to the efflux pump was evaluated.

Results

The E. coli isolates demonstrated high resistance to ampicillin (100%), cefixime (62%), cefepime (62%), amoxicillin-clavulanic acid (60%), cefuroxime (60%), and ceftriaxone (58%). The susceptibility of E. coli to ertapenem was greatest (92%), followed by imipenem (88%), meropenem (86%), tigecycline (80%), and levofloxacin (76%). Regarding efflux pump gene combinations, there was a significant association between the acrA gene and increased resistance to levofloxacin, between the acrB gene and decreased resistance to meropenem and increased resistance to levofloxacin, and between the ompF and ompC genes and increased resistance to gentamicin.

Conclusions

The antibiotics ertapenem, imipenem, meropenem, tigecycline, and levofloxacin were effective against E. coli in patients with COVID-19. Genes encoding efflux pumps and porins, such as acrA, acrB, and outer membrane porins, were highly distributed among all the isolates. Efflux pump inhibitors could be alternative antibiotics for restoring tetracycline activity in E. coli isolates.

Peer Review reports

Background

Coronavirus disease 2019 (COVID-19) is an acute respiratory infection that can potentially cause serious complications caused by severe acute respiratory syndrome coronavirus 2, known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1]. The severity of the disease in SARS-CoV-2-infected patients spans a wide range and has spread throughout the world, making it a severe threat to public health from a carrier state without obvious symptoms to a life-threatening case of severe respiratory tract infection [2].

A secondary bacterial infection could result in a lower discharge rate and increased mortality [3]. Critically ill patients with COVID-19 are at high risk of secondary bacterial infection, such as secondary pneumonia, ventilator-assisted pneumonia, bloodstream infections, and even device-related secondary infections, during prolonged stays in intensive care units [4]. It has been hypothesized that patients with COVID-19 in critical care are at an even greater risk of developing secondary infections due to immunosuppression caused by the virus or drugs [5].

Determining the causal microorganisms responsible for secondary bacterial infections in critically ill patients with COVID-19 presents additional opportunities for investigation, such as empirical antibiotic treatment specifically designed for patients exhibiting initial signs of a secondary infection. Identifying potential risk factors related to secondary bacterial infections could help create novel techniques for prevention [6, 7].

The prevalence of secondary bacterial infection is approximately 10%-15% and is most common in coinfections and secondary infections [8]. Escherichia coli (E. coli) is one of the most common infectious disease agents and an important public health risk posed by alarmingly high rates of antibiotic resistance [9, 10]. The development of antibiotic resistance is a complicated and multifaceted process [11]. However, this process evolves due to prolonged exposure to antibiotics. Selective pressure has led to the evolution of various genetic mechanisms [12]. The resistance of E. coli to various antibiotics results from a complex interplay of factors, such as the modification of antibiotic targets, activation of efflux pump systems, membrane impermeability, and release of antibiotic-inactivated enzymes [13, 14]. Within these vital mechanisms, efflux pump systems play an important role in developing multidrug resistance by increasing antibiotic transport outside the cell through efflux pumps and porins [15, 16].

Efflux pump protein-based structures play a crucial role in bacterial physiology by mediating the uptake and excretion of essential nutrients, toxic substances, metabolic waste, and decreased antibiotic influx into the cell through changes in cell wall structure [17]. Generally, bacterial efflux pump systems can be divided into six different groups: the cassette superfamily of the adenosine triphosphate-binding cassette superfamily; multidrug and toxic compound extrusion; the major facilitator superfamily; small multidrug resistance; the resistance nodulation division family, which can extrude aminoglycosides, fluoroquinolones, and B-lactams; and the proteasomal antimicrobial compound efflux family [14].

The AcrAB-TolC efflux pump, a member of the resistance nodulation division family, is the main efflux pump in virulent strains of E. coli [18]. This pump comprises three important parts: the periplasmic membrane fusion protein AcrA, the inner membrane protein transporter AcrB, and the outer membrane channel TolC [19]. The AcrAD-TolC efflux pump has been reported to play an important role in resistance to different groups of antibiotics, such as aminoglycoside, fluoroquinolone, tetracycline, β-lactam, and carbapenem antibiotics [20,21,22]. However, outer membrane porins are closely associated with antibiotic resistance because they facilitate the passive diffusion of antibiotics through the outer membrane. Moreover, OmpC and OmpF are nonspecific porins involved in antibiotic transport and membrane integrity [23].

Although numerous studies have examined the epidemiological and clinical characteristics of coronavirus disease, data on secondary bacterial infections have been scarce [24, 25]. Therefore, this study aimed to determine the antimicrobial resistance profile of E. coli as a secondary bacterial infection in COVID-19 patients from Erbil city, Iraq, and the prevalence of genes related to pump and porin efflux among the E. coli isolates studied.

Methods

Bacterial isolation and study design

Fifty E. coli isolates were collected from patients with COVID-19 pneumonia who were hospitalized in the intensive care unit of one hospital in Erbil city, Iraq, between December 2020 and November 2021. All patients with COVID-19 and secondary E. coli infection in the studied hospital were included. The Research Ethics Committee of the College of Pharmacy of Hawler Medical University approved the study. Due to the retrospective nature of the study and the urgency of collecting data during the pandemic, initial verbal informed consent was waived. Finally, written consent was obtained from participants at a later stage. These isolates were identified by conventional and biochemical tests and confirmed by Vitek 2 (bioMerieux, USA) (GN-card) [6, 26].

Antibacterial susceptibility test

The susceptibility of the E. coli isolates to antibiotics was assessed by the Vitek 2 system (bio-Mérieux, Inc., Durham, NC, USA) based on AST-GN69 and the AST-XN06 cards according to the manufacturer’s instructions. The antibiotics tested included ampicillin (AMP), amoxicillin-clavulanic acid (AMX-C), piperacillin/tazobactam, amikacin (AMK), gentamicin (GEN), meropenem (MEM), imipenem (IPM), ertapenem (ETP), ciprofloxacin (CIP), LEV, TG, trimethoprim-sulfamethoxazole, ceftazidime, cefepime (CFP), ceftriaxone (CFN), cefuroxime (CXM), and cefixime (CFX) [27].

Efflux pump activity assay

The minimum inhibitory concentration (MIC) of tetracycline was calculated in 96-well plates using a broth microdilution method based on the Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing 2021 [28]. According to the manufacturer's instructions, the tetracycline powder was dissolved in sterilized deionized water. The concentrations used were then 256, 128, 64, 32, 16, 8, 4, 2, 0.5, and 0.25 µg/mL. Then, 100 µL of the produced dilutions were added to each well of the 96-well microplate. The microbial suspension was concentrated to 0.5 McFarland standard and diluted at a ratio of 1/100. The plates were then incubated at 35 °C for 18 - 24 h, with 100 µL of microbial suspension was added to each well. The MIC was defined as the lowest antibiotic concentration that prevented growth [29]. A final concentration of 12 µg/mL carbonyl cyanide 3-chlorophenylhydrazone (CCCP) inhibitor was added to each Muller Hinton broth containing 0.25 - 256 µg/mL tetracycline. This concentration was used as a sub-MIC of CCCP after optimization by using several concentrations of CCCP to inhibit bacterial isolates. Tetracycline was used as an indicator for genes related to efflux, as previously described [30]. After CCCP therapy, the antibiotic MICs were measured once more. The fourfold decrease in the MIC after the application of the CCCP inhibitor was interpreted as an indicator of substantial efflux pump activity. The control sample was a CCCP-containing, antibiotic-free plate [31].

Molecular analysis

The strains were stored at -70 °C in 20% (vol/vol) glycerol in BHI medium and grown overnight on MacConkey agar at 37 °C to retain genetic variation. A bacterial colony was suspended in 500 µl of distilled water. The DNA extraction kit (G-nad and Beta Bayern) was used as directed by the manufacturer. The DNA was stored at -20 °C until needed. The primer sets to detect key efflux pump genes (Table 1) were used as previously described [32,33,34].

Table 1 Primer sequences, product sizes, and annealing temperatures of target genes of the isolates used in this study
Full size table

For PCR, 3 µl of entire genomic DNA (5 µl of nucleus-free water, 10 µl of master mix, and 1 µl per primer) was used as a template. A standard PCR amplification program was used on a thermocycler (Eppendorf, M Germany) as follows: initial heating to 95 °C for 5 min, followed by 30 amplification cycles. Each cycle consisted of three phases: denaturation at 95 °C for 30 s, annealing at 56 °C for 30 s, and extension at 72 °C for an adequate time, followed by a final 5-min step of elongation at 72 °C. Finally, the PCR products were stored at 4 °C until further analysis. The PCR products were electrophoresed on a 1% agarose gel, stained with ethidium bromide, and visualized using a UV transilluminator.

Statistical analysis

Continuous data are shown as mean ± standard deviation (SD). Categorical data were analyzed using Chi-square and Fisher's exact tests and are presented as frequencies and percentages. A P value < 0.05 was considered to indicate statistical significance.

Results

The preliminary identification of the 50 E. coli strains from the sputum sample of COVID-19 patients as secondary bacterial infections was carried out according to their morphological and biochemical characteristics. Then, all the isolates were confirmed using the Vitek 2 system. The mean ± SD age of the patients was 48.9 (18.1) years (range 14-90 years). Most of the patients were 41-50 years old (34%), male (58%), and from urban areas (78%), as shown in Table 2.

Table 2 Descriptive characteristics of the study sample
Full size table

Table 3 shows the changes in the fold reductions of the positive isolates. A two-fold or greater reduction in the MIC of the antimicrobial agent when CCCP is added in place of the antibiotic is considered the criterion of significance. The greatest reduction in the MIC was 8 times and was observed for four isolates, followed by a 7 times reduction for only one isolate. The highest number of isolates (10) had a threefold reduction, followed by seven isolates with a fourfold reduction.

Table 3 Detection of efflux pump resistance to tetracycline in E. coli
Full size table

Table 4 shows the resistance rates the of E. coli isolates to a variety of antibiotics. E. coli isolates demonstrated high resistance to AMP (100%), CFX and CFP (62%), AMX-C and CXM (60%), and CFN (58%). The susceptibility of E. coli was highest for ETP (92%), followed by IPM (88%), MEM (86%), TG (80%), and LEV (76%).

Table 4 E. coli antibiotic resistance rate in patients with COVID-19
Full size table

The data produced from this study showed that carbapenem antibiotics, both IMP and MEM, are still 2 of the best antibiotics against the pathogen under study, as they are highly effective antibiotics. Genomic data from this investigation showed that acrA (820 bp) was the most common gene detected in the isolates (74.0%), followed by acr B (890 bp) (64.0%), ompC (162 bp) (48%), ompF (191 bp) (32%), and tolC (655 bp) (24%), as shown in Table 5.

Table 5 Distribution of the efflux pump and porin genes among the E. coli isolates
Full size table

acrA and acrB were the most common combinations of genes among the isolates (20%). The three (6%) isolates did not amplify any of the genes tested (Table 6).

Table 6 Distribution of efflux pump and porin gene combinations among E. coli strains
Full size table

Table 7 shows the associations between resistance to different antibiotics and the gene groups of E. coli. The acrA gene was significantly associated with increased resistance to levofloxacin (P = 0.022). The acrB gene was significantly associated with decreased resistance to meropenem (P = 0.006) and increased resistance to levofloxacin (P = 0.036). The ompF gene was significantly associated with increased resistance to gentamicin (P = 0.001). The ompC gene was significantly associated with increased resistance to gentamicin (P = 0.048). ThetolC gene was significantly associated with higher resistance to gentamicin (P = 0.004), meropenem (0.048), imipenem (P = 0.024), and tigecycline (P = 0.046).

Table 7 Association between resistance to different antibiotics and the gene groups
Full size table

Discussion

Previous viral outbreaks and pandemics were associated with increased morbidity and mortality primarily due to secondary bacterial infections. Most of the patient deaths during the 1918–1919 influenza pandemic were caused by secondary bacterial infections rather than viral infections [37]. With symptoms ranging from a mild flu-like illness to acute respiratory distress syndrome, COVID-19 generally manifests as a respiratory tract infection. The causes of bacterial and fungal coinfection in hospitalized patients with COVID-19 are unclear. Fifteen percent of hospitalized patients in Wuhan experienced secondary bacterial infections related to COVID-19; these infections were more common in non-survivors than in survivors [38]. More secondary bacterial and fungal infections, particularly infections caused by Haemophilus influenzae, Streptococcus pneumoniae, Staphylococcus aureus, and Aspergillus spp., have been reported during viral (influenza) pneumonitis epidemics. These infections are commonly associated with poor patient outcomes [39]. Gram-negative bacilli, primarily Pseudomonas aeruginosa, Enterobacter species, and E. coli, were shown to be the most prevalent bacteria that cause secondary pneumonia in patients with COVID-19 according to a major multicenter study conducted in 36 European intensive care units [40].

This study revealed that COVID-19 patients with microbiologically examined infections had E. coli bacteria, consistent with a study finding that 7.0% of COVID-19 patients had secondary bacterial infections caused by E. coli [41]. According to the current study, E. coli isolates are extremely susceptible to carbapenem antibiotics, including IPM, MEM, and ETP (88, 86, and 92%, respectively). However, they demonstrated complete resistance to AMP, 60% resistance to AMX-C acid, and significant resistance to cephalosporins, GEN, and AMK. According to other studies, ESBL-producing bacteria are known to produce a significant level of antibiotic resistance in E. coli [42, 43].

A key element contributing to the increase in antimicrobial resistance is the inappropriate prescription of antibiotics. Among several chemicals used as efflux pump inhibitors, phenylalanine arginine-naphthylamide or CCCP are the most commonly used to assess the effect of the AcrAB efflux pump on drug resistance in E. coli strains [44]. This study evaluated the MICs of tetracycline with and without CCCP as an AcrAB efflux pump inhibitor. Approximately 90% of the E. coli isolates were cultured in the presence of CCCP and became less resistant to tetracycline.

A considerable loss in antibacterial activity (four to eightfold reduction) was reported in 18 (36% of isolates), indicating that the efflux mechanism plays an important role in resistance to tetracyclines. In agreement with our results, Hao et al. reported that some E. coli strains were resistant to all prevalent antibiotics except TG, including B-lactams, tetracycline, fluoroquinolones, aminoglycosides, polymyxin B (8 g / mL) and fluoroquinolones [45]. They showed that after adding CCCP at 10 g / ml, the MIC of GEN was reduced by twofold, while the MIC of MEM, tetracycline, CIP, and chloramphenicol decreased by fourfold. Meena et al. evaluated the multiple antibiotic resistance index and the resistance mechanism of multidrug-resistant E. coli isolates from chicken feces [46]. They reported that the four antibiotics they used in their study, ceftazidime, tetracycline, chloramphenicol, and streptomycin, all reduced the growth of all isolates when taken in conjunction with CCCP. However, no absolute efflux, or 100% reduction, was observed. A reduction in the amount of porins may cause this multidrug phenotype, together with other mechanisms that restrict the entry of antibiotics into the bacterial cell. As a result, it was established that active efflux pumps play a role in the antibiotic resistance process. This finding is also consistent with the findings of a study conducted in Ohio, USA, which reported that after growing E. coli isolates for several generations in increasing concentrations of CCCP when evolved strains were grown in the presence of different antibiotics, one of the strains was very sensitive to tetracycline and chloramphenicol due to a mutation in the acrB gene detected by whole genome sequencing [47]. In contrast, other evolved strains showed mutations in the multidrug-resistant components acrAB and ybhR. Similarly, another study reported that antibiotic activity was induced in the presence of CCCP (10 mg/L final concentration). CCCP restored the activity of tetracycline against Klebsiella spp., and the MIC of the bacteria decreased from 512 mg/L to 53.15 mg/L [48]. CCCP has been reported to deter the proton motive force through its effect on the transmembrane potential and the transmembrane pH [49]. Thus, bacterial cells are metabolically deactivated. It is not clear whether the synergism of CCCP with a variety of antibiotics is caused by bacterial cell metabolic deactivation or efflux pump deactivation. CCCP could restore tetracycline activity against Klebsiella spp. and Helicobacter pylori [50].

It has been proposed that CCCP causes the formation of metabolically inert cells, resulting in synergistic effects with antibiotics. Due to this and cellular toxicity to mammalian cells, CCCP has been restricted to laboratory use only [51]. Another barrier that efflux pump inhibitors may face in becoming a viable treatment option is the unavailability of preclinical and clinical data. There is a paucity of information available on in vivo models and patient data to complement efflux pump inhibitor activity. Nevertheless, CCCP is the most widely used laboratory efflux pump inhibitor [50]. Multidrug efflux pumps are critical for developing resistance to many antibiotic classes [52]. They function at the frontline to protect bacteria against antibiotics by reducing the intracellular concentration of drugs [53].

This study showed that most of the genes related to the efflux pump are present in E. coli isolates. AcrA, acrB, tolC, omp F, and ompC were found in 74% (37/50), 64% (32/50), 24% (12/50), 32% (16/50), and 48% (24/50) of the clinical isolates, respectively. Similarly, Fayyazi et al. 2020 reported that 78.4%, 89.2%, and 82.9% of the isolates were positive for acrA, acrB, and tolC, respectively [54]. The current investigation revealed that acrA and acrB were found in 20% of the clinical isolates tested, while acrA, acrB, ompF, and ompC were found in 12% of the clinical isolates. In contrary, investigations in Egypt revealed that acrA and acrB were present in 74.28% of the clinical isolates of uropathogenic E. coli examined [35]. Additionally, unlike findings from Iran, the copresence of acrA-B was found in 95.9% of the E. coli isolates [55]. As a result, new strategies for modulating these resistance nodulation division efflux pumps, such as AcrAB-TolC, are required since they are crucial in gram-negative bacteria and for removing hazardous chemicals and medications. For example, resistance nodulation division transporters play an important role in mediating bacterial resistance to antibiotics and heavy metals. Furthermore, a mutation in specific amino acid residues in strategic domains of these efflux pumps may represent a mechanism to reduce or inhibit the affinity of the efflux pump for their usual substrates, improving multidrug resistance [56]. Sulavik et al. (2001) created E. coli strains with null mutations in efflux pump genes. These findings agreed with the hypothesis that tolC contributes to intrinsic resistance with and without AcrAB. They also discovered that the overlapping substrate susceptibility profiles of the acrAB and tolC mutant strains support their interaction as a tripartite pump system [57]. E. coli K-12 has also been reported to have at least 20 multidrug efflux pump genes that confer resistance once overexpressed [56].

Porin has been shown to play a different role in membrane integrity, antibiotic resistance, or both. Many antibiotics, for example, use ompF as the primary mechanism of outer membrane penetration. However, ompA was significantly linked to membrane integrity, increasing the susceptibility of the ompA mutant to numerous antibiotics. OmpC was found to be important for both antibiotic resistance and membrane integrity [58]. It has been reported that genetic mutations can change the expression of major porins, resulting in a reduction in porin expression or complete loss of these porins. Porin loss is the main source of resistance to various antibiotics, particularly b-lactams [59]. Porins mediate the inflow of nutrients and several antimicrobial drugs in gram-negative bacteria, and the sensitivity of bacteria to antibiotics is greatly influenced by the porins’ permeability characteristics [23]. A recent study by Ejaz revealed the effect of porin loss on the development of resistance and suggested the mechanisms for such resistance development. It revealed that Klebsiella pneumoniae strains with OmpK35 and OmpK36 porin loss show conglomerate resistance mechanisms with AmpC and carbapenemases, resulting in the emergence of extensive drug resistance. This makes these strains resistant to many antibiotics, including carbapenem [59]. Carbapenem resistance is reportedly related to porin loss independent of carbapenemase production [60, 61]. Such extensive resistance related to these suggested mechanisms may pose serious therapeutic problems, with limited therapeutic options remaining in the future [59, 60].

The present study has a number of limitations. The study was conducted in a single hospital during the COVID-19 epidemic due to the lack of access to other hospitals. The types of patients, secondary bacterial infections, and antibiotic resistance might have been different in other patients and hospitals, limiting the generalizability of our findings. We assessed the MIC of only tetracycline, although the resistance profile showed resistance to many antibiotics, and similar studies have assessed the effect of CCCP on the MICs of several other antibiotics. It could be more helpful to increase the number of antibiotics tested and evaluate the effect of CCCP on the MICs of more antibiotics based on resistance profiles. This study did not use any control strains due to their unavailability in the Kurdistan Region of Iraq when conducting this study. This is another limitation of this study, which could impact the study outcomes.

Conclusions

Secondary bacterial infection among patients with COVID-19 is a serious problem. With increasing antimicrobial resistance among these secondary infectious pathogens, infection control and antimicrobial stewardship measures must be reinforced. It has been concluded from the present study that E. coli isolates exhibit a high prevalence of resistance to the antibiotics ampicillin, cefixime, cefepime, amoxicillin-clavulanic acid, cefuroxime, and ceftriaxone. Our results indicate that efflux pumps and porins play a significant role in E. coli antibiotic resistance, which is worrisome and highlights the urgent need for future studies using efflux pump inhibitors in combination with antibiotics. Understanding the epidemiological patterns of secondary bacterial infection in patients with COVID-19 is critical for providing appropriate therapy and preventing the overuse of antibiotics for treating patients. The current study revealed that the antibiotics ertapenem, imipenem, meropenem, tigecycline, and levofloxacin were effective against E. coli in patients with COVID-19. Genes encoding efflux pumps and porins, such as acrA, acrB, and omp, were highly distributed among all the isolates. Efflux pump inhibitors could be alternative antibiotics for restoring tetracycline activity in E. coli isolates. More work is needed to identify new efflux pump inhibitors that could be used to treat such infections.

Availability of data and materials

All the data, including the values and numbers used to produce the results, are available upon reasonable request.

Abbreviations

AMP:

Ampicillin

AMX-C:

Amoxicillin-clavulanic acid

CCCP:

Carbonyl cyanide 3-chlorophenylhydrazone

CFN:

Ceftriaxone

CFP:

Cefepime

CFX:

Cefixime

COVID-19:

Coronavirus disease 2019

CXM:

Cefuroxime

E. coli :

Escherichia coli

ETP:

Ertapenem

GEN:

Gentamicin

IPM:

Imipenem

LEV:

Levofloxacin

MEM:

Meropenem

MIC:

Minimum inhibitory concentration

Omp:

Outer membrane protein

PCR:

Polymerase chain reaction

TG:

Tigecycline

References

  1. Idoko OT, Usuf E, Okomo U, Wonodi C, Jambo K, Kampmann B, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Africa: current considerations and future projections. Clin Infect Dis. 2022;75(Supplement_1):S136–40.

    Article  PubMed  Google Scholar 

  2. Chams N, Chams S, Badran R, Shams A, Araji A, Raad M, et al. COVID-19: a multidisciplinary review. Front Public Health. 2020;8:383.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Ng QX, Ong NY, Lee DYX, Yau CE, Lim YL, Kwa ALH, et al. Trends in Pseudomonas aeruginosa (P. aeruginosa) bacteremia during the COVID-19 pandemic: a systematic review. Antibiotics (Basel). 2023;12(2):409.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Kim M, Cardoso FS, Pawlowski A, Wunderink R, Ladner DP, Abraldes JG, et al. The impact of multidrug-resistant microorganisms on critically ill patients with cirrhosis in the intensive care unit: a cohort study. Hepatol Commun. 2023;7(2):e0038.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Viale P, Sandrock CE, Ramirez P, Rossolini GM, Lodise TP. Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence. Ann Intensive Care. 2023;13(1):1–25.

    Article  Google Scholar 

  6. De Bruyn A, Verellen S, Bruckers L, Geebelen L, Callebaut I, De Pauw I, et al. Secondary infection in COVID-19 critically ill patients: a retrospective single-center evaluation. BMC Infect Dis. 2022;22:207.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Povoa P, Martin-Loeches I, Nseir S. Secondary pneumonias in critically ill patients with COVID-19: risk factors and outcomes. Curr Opin Crit Care. 2021;27(5):468.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Gerver SM, Guy R, Wilson K, Thelwall S, Nsonwu O, Rooney G, et al. National surveillance of bacterial and fungal coinfection and secondary infection in COVID-19 patients in England: lessons from the first wave. Clin Microbiol Infect. 2021;27(11):1658–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Laconi A, Tolosi R, Apostolakos I, Piccirillo A. Biofilm formation ability of ESBL/pAmpC-producing Escherichia coli isolated from the broiler production pyramid. Antibiotics (Basel). 2023;12(1):155.

    Article  CAS  PubMed  Google Scholar 

  10. Ganjo AR. Extended-Spectrum β-lactamases and AmpC Production among Uropathogenic Isolates of Escherichia coli and Antibiogram Pattern. ARO Scie J Koya Univ. 2022;10(1):98–103.

    Google Scholar 

  11. Biondo C. New insights into bacterial pathogenesis. Pathogens. 2023;12(1):38.

    Article  Google Scholar 

  12. Webber MA, Whitehead RN, Mount M, Loman NJ, Pallen MJ, Piddock LJ. Parallel evolutionary pathways to antibiotic resistance selected by biocide exposure. J Antimicrob Chemother. 2015;70(8):2241–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Saha M, Sarkar A. Review on multiple facets of drug resistance: a rising challenge in the 21st century. J Xenobiot. 2021;11(4):197–214.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Tabcheh J, Vergalli J, Davin-Régli A, Ghanem N, Pages J-M, Al-Bayssari C, et al. Rejuvenating the activity of usual antibiotics on resistant gram-negative bacteria: recent issues and perspectives. Int J Mol Sci. 2023;24(2):1515.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Shriram V, Khare T, Bhagwat R, Shukla R, Kumar V. Inhibiting bacterial drug efflux pumps via phyto-therapeutics to combat threatening antimicrobial resistance. Front Microbiol. 2018;9:2990.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Masi M, Réfregiers M, Pos KM. Mechanisms of envelope permeability and antibiotic influx and efflux in gram-negative bacteria. Nat Microbiol. 2017;2(3):1–7.

    Article  Google Scholar 

  17. Olubisose ET, Ajayi A, Adeleye AI, Smith SI. Molecular and phenotypic characterization of efflux pump and biofilm in multidrug resistant nontyphoidal Salmonella Serovars isolated from food animals and handlers in Lagos Nigeria. One Health Outlook. 2021;3:1–8.

    Article  Google Scholar 

  18. Chetri S, Bhowmik D, Paul D, Pandey P, Chanda DD, Chakravarty A, et al. AcrAB-TolC efflux pump system plays a role in carbapenem nonsusceptibility in Escherichia coli. BMC Microbiol. 2019;19(1):210.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Abdali N, Parks JM, Haynes KM, Chaney JL, Green AT, Wolloscheck D, et al. Reviving antibiotics: efflux pump inhibitors that interact with AcrA, a membrane fusion protein of the AcrAB-TolC multidrug efflux pump. ACS Infect Dis. 2017;3(1):89–98.

    Article  CAS  PubMed  Google Scholar 

  20. Daury L, Orange F, Taveau J-C, Verchère A, Monlezun L, Gounou C, et al. Tripartite assembly of RND multidrug efflux pumps. Nat Commun. 2016;7(1):10731.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Yılmaz Ç, Özcengiz G. Antibiotics: pharmacokinetics, toxicity, resistance and multidrug efflux pumps. Biochem Pharmacol. 2017;133:43–62.

    Article  PubMed  Google Scholar 

  22. Auda IG, Salman IMA, Odah JG. Efflux pumps of gram-negative bacteria in brief. Gene Reports. 2020;20:100666.

    Article  CAS  Google Scholar 

  23. Zhou G, Wang Q, Wang Y, Wen X, Peng H, Peng R, et al. Outer membrane porins contribute to antimicrobial resistance in gram-negative bacteria. Microorganisms. 2023;11(7):1690.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Bardi T, Pintado V, Gomez-Rojo M, Escudero-Sanchez R, Azzam Lopez A, Diez-Remesal Y, et al. Nosocomial infections associated with COVID-19 in the intensive care unit: clinical characteristics and outcome. Eur J Clin Microbiol Infect Dis. 2021;40:495–502.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Do TV, Manabe T, Vu GV, Nong VM, Fujikura Y, Phan D, et al. Clinical characteristics and mortality risk among critically ill patients with COVID-19 owing to the B. 1.617. 2 (Delta) variant in Vietnam: a retrospective observational study. PloS One. 2023;18(1):e0279713.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Jomehzadeh N, Jahangirimehr F, Chegeni SA. Virulence-associated genes analysis of carbapenemase-producing Escherichia coli isolates. PLoS One. 2022;17(5):e0266787.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Medugu N, Aworh MK, Iregbu K, Nwajiobi-Princewill P, Abdulraheem K, Hull DM, et al. Molecular characterization of multi drug resistant Escherichia coli isolates at a tertiary hospital in Abuja, Nigeria. Sci Rep. 2022;12(1):14822.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. CLSI. Performance standards for antimicrobial susceptibility testing, M100. 31st ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2021.

    Google Scholar 

  29. Tintino SR, Morais-Tintino CD, Campina FF, Costa MDS, Menezes IR, de Matos YML, et al. Tannic acid affects the phenotype of Staphylococcus aureus resistant to tetracycline and erythromycin by inhibition of efflux pumps. Bioorg Chem. 2017;74:197–200.

    Article  CAS  PubMed  Google Scholar 

  30. Beheshti M, Ardebili A, Beheshti F, Lari AR, Siyadatpanah A, Pournajaf A, Gautam D, Dolma KG, Nissapatorn V. Tetracycline resistance mediated by tet efflux pumps in clinical isolates of Acinetobacter baumannii. Rev Inst Med Trop Sao Paulo. 2020;62:e88.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Jahromy SH, Ranjbar S, Pishkar L. Phenotypic activity of efflux pumps by Carbonyl Cyanide MChlorophenyl Hydrazone (CCCP) and mutations in GyrA and ParC genes among ciprofloxacin-resistant Acinetobacter baumannii isolates. Jundishapur J Microbiol. 2020;13(4):e99435.

  32. Chowdhury N, Suhani S, Purkaystha A, Begum MK, Raihan T, Alam MJ, et al. Identification of AcrAB-TolC efflux pump genes and detection of mutation in efflux repressor AcrR from omeprazole responsive multidrug-resistant Escherichia coli isolates causing urinary tract infections. Microbiol Insights. 2019;12:1178636119889629.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Chetri S, Singha M, Bhowmik D, Nath K, Chanda DD, Chakravarty A, et al. Transcriptional response of OmpC and OmpF in Escherichia coli against differential gradient of carbapenem stress. BMC Res Notes. 2019;12(1):1–6.

    Article  Google Scholar 

  34. Guo X, Murray M, Xiong C, Zhu S. Treatment of Escherichia coli BW25113 with subinhibitory levels of kanamycin results in antibiotic cross resistance and TolC upregulation. J Exp Microbiol Immun. 2013;17:19–23.

    Google Scholar 

  35. Gawad WE, Helmy OM, Tawakkol WM, Hashem AM. Antimicrobial resistance, biofilm formation, and phylogenetic grouping of uropathogenic Escherichia coli isolates in Egypt: the role of efflux pump-mediated resistance. Jundishapur J Microbiol. 2018;11(2):e14444.

  36. Zhang Y, Gu AZ, He M, Li D, Chen J. Subinhibitory concentrations of disinfectants promote the horizontal transfer of multidrug resistance genes within and across genera. Environ Sci Technol. 2017;51(1):570–80.

    Article  CAS  PubMed  Google Scholar 

  37. Taubenberger JK, The MDM. influenza pandemic and its legacy. Cold Spring Harb Perspect Med. 1918;2019:a038695.

    Google Scholar 

  38. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan. China Intensive Care Med. 2020;46(5):846–8.

    Article  CAS  PubMed  Google Scholar 

  39. Hughes S, Troise O, Donaldson H, Mughal N, Moore LS. Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting. Clin Microbiol Infect. 2020;26(10):1395–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Rouzé A, Martin-Loeches I, Povoa P, Makris D, Artigas A, Bouchereau M, et al. Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study. Intensive Care Med. 2021;47:188–98.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Rajni E, Garg VK, Bacchani D, Sharma R, Vohra R, Mamoria V, et al. Prevalence of bloodstream infections and their etiology in COVID-19 patients admitted in a Tertiary Care Hospital in Jaipur. Indian J Crit Care Med. 2021;25(4):369.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. El-Baz R, Said HS, Abdelmegeed ES, Barwa R. Characterization of virulence determinants and phylogenetic background of multiple and extensively drug resistant Escherichia coli isolated from different clinical sources in Egypt. Appl Microbiol Biotechnol. 2022;106(3):1279–88.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Asmarawati TP, Rosyid AN, Suryantoro SD, Mahdi BA, Windradi C, Wulaningrum PA, et al. The clinical impact of bacterial coinfection among moderate, severe and critically ill COVID-19 patients in the second referral hospital in Surabaya. F1000Research. 2021;10:113.

  44. Rajan PP, Sreekantan AP, Mini M, Khan S, Kumar P. Multi-Drug Resistant Escherichia coli and Proteus mirabilis from Thiruvananthapuram, Kerala (India). Appl Biol Res. 2022;24(4):440–7.

    Article  Google Scholar 

  45. Hao J, Zeng Z, Xiao X, Ding Y, Deng J, Wei Y, et al. Genomic and phenotypic characterization of a colistin-resistant Escherichia coli isolate coharboring bla NDM-5, bla OXA-1, and bla CTX-M-55 isolated from urine. Infect Drug Resist. 2022;15:1329–43.

  46. Meena R, Jangir K, Kashyap SK. Evaluation of efflux activity in multi drug resistant commensal Escherichia coli isolated from poultry. J Entomol Zool Stud. 2020;8(4):1298–301.

    Google Scholar 

  47. Griffith JM, Basting PJ, Bischof KM, Wrona EP, Kunka KS, Tancredi AC. Experimental evolution of Escherichia coli K-12 in the presence of proton motive force (PMF) uncoupler carbonyl cyanide m-chlorophenylhydrazone selects for mutations affecting PMF-driven drug efflux pumps. Appl Environ Microbiol. 2019;85(5):e02792–e2818.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Fenosa A, Fusté E, Ruiz L, Veiga-Crespo P, Vinuesa T, Guallar V, et al. Role of TolC in Klebsiella oxytoca resistance to antibiotics. J Antimicrob Chemother. 2009;63(4):668–74.

    Article  CAS  PubMed  Google Scholar 

  49. Bhattacharyya T, Sharma A, Akhter J, Pathania R. The small molecule IITR08027 restores the antibacterial activity of fluoroquinolones against multidrug-resistant Acinetobacter baumannii by efflux inhibition. Int J Antimicrob Agents. 2017;50(2):219–26.

    Article  CAS  PubMed  Google Scholar 

  50. Thakur V, Uniyal A, Tiwari V. A comprehensive review on pharmacology of efflux pumps and their inhibitors in antibiotic resistance. Eur J Pharmacol. 2021;903:174151.

    Article  CAS  PubMed  Google Scholar 

  51. Osei Sekyere J, Amoako DG. Carbonyl cyanide m-chlorophenylhydrazine (CCCP) reverses resistance to colistin, but not to carbapenems and tigecycline in multidrug-resistant Enterobacteriaceae. Front Microbiol. 2017;8:228.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Nolivos S, Cayron J, Dedieu A, Page A, Delolme F, Lesterlin C. Role of AcrAB-TolC multidrug efflux pump in drug-resistance acquisition by plasmid transfer. Science. 2019;364(6442):778–82.

    Article  CAS  PubMed  Google Scholar 

  53. Huang L, Wu C, Gao H, Xu C, Dai M, Huang L, et al. Bacterial multidrug efflux pumps at the frontline of antimicrobial resistance: An overview. Antibiotics (Basel). 2022;11(4):520.

    Article  CAS  PubMed  Google Scholar 

  54. Fayyazi A, Halaji M, Sadeghi A, Havaei SA. High frequency of integrons and efflux pump in uropathogenic Escherichia coli isolated from Iranian kidney and nonkidney transplant patients. Gene Rep. 2020;21:100873.

    Article  CAS  Google Scholar 

  55. Kafilzadeh F, Farsimadan F. Investigating multidrug efflux pumps in relation to the antibiotic resistance pattern in Escherichia coli strains from patients in Iran. Biomed Res. 2016;27(4):1130–5.

    CAS  Google Scholar 

  56. De Gaetano GV, Lentini G, Famà A, Coppolino F, Beninati C. Antimicrobial resistance: two-component regulatory systems and multidrug efflux pumps. Antibiotics (Basel). 2023;12(6):965.

    Article  PubMed  Google Scholar 

  57. Sulavik MC, Houseweart C, Cramer C, Jiwani N, Murgolo N, Greene J. Antibiotic susceptibility profiles of Escherichia coli strains lacking multidrug efflux pump genes. Antimicrob Agents Chemother. 2001;45(4):1126–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Choi U, Lee C-R. Distinct roles of outer membrane porins in antibiotic resistance and membrane integrity in Escherichia coli. Front Microbiol. 2019;10:953.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Ejaz H. Analysis of diverse β-lactamases presenting high-level resistance in association with OmpK35 and OmpK36 porins in ESBL-producing Klebsiella pneumoniae. Saudi J Biol Sci. 2022;29(5):3440–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Meletis G. Carbapenem resistance: overview of the problem and future perspectives. Ther Adv Infect Dis. 2016;3(1):15–21.

    CAS  PubMed  PubMed Central  Google Scholar 

  61. Müller M, Wiencierz A, Gehringer C, Muigg V, Bassetti S, Siegemund M, et al. Factors associated with non-carbapenemase mediated carbapenem resistance of Gram-negative bacteria: a retrospective case-control study. Int Microbiol. 2023. https://doi.org/10.1007/s10123-023-00405-6.

Download references

Acknowledgements

Not applicable.

Funding

Not applicable.

Author information

Authors and Affiliations

  1. Department of Clinical Analysis, College of Pharmacy, Hawler Medical University, Erbil, Kurdistan Region, Iraq

    Aryan R. Ganjo

  2. Department of Medical Analysis, Faculty of Applied Science, Tishk International University, Erbil, Iraq

    Aryan R. Ganjo & Salah Tofik Jalal Balaky

  3. Department of Medical Microbiology, College of Health Sciences, Hawler Medical University, Erbil, Kurdistan Region, Iraq

    Salah Tofik Jalal Balaky & Ahang Hasan Mawlood

  4. Department of Medical Laboratory Technique, College of Medical Technology, AL-Kitab University, Kirkuk, Iraq

    Ahang Hasan Mawlood

  5. Par Hospital, Erbil, Kurdistan Region, Iraq

    Sakar B. Smail

  6. College of Health Sciences, Catholic University in Erbil, Erbil, Kurdistan Region, Iraq

    Nazar P. Shabila

  7. Department of Community Medicine, College of Medicine, Hawler Medical University, Erbil, Iraq

    Nazar P. Shabila

Authors
  1. Aryan R. Ganjo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Salah Tofik Jalal Balaky
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ahang Hasan Mawlood
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sakar B. Smail
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nazar P. Shabila
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

STJB designed the study and supervised the whole work. ARG, SBS, and AHM participated in sample collection, culture and drug sensitivity testing, and other practical parts. NPS performed data analysis, drafted part of the manuscript, and proofread and finalized the manuscript. ARG and AHM contributed to drafting the manuscript. All the authors have read and approved the final manuscript.

Corresponding author

Correspondence to Salah Tofik Jalal Balaky.

Ethics declarations

Ethics approval and consent to participate

This study was approved by the Research Ethics Committee of the College of Pharmacy of Hawler Medical University (number: HMUPHEC-20200812–87). Written informed consent was obtained from the participants prior to participation in the study. All methods were carried out in accordance with relevant guidelines and regulations.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ganjo, A.R., Balaky, S.T.J., Mawlood, A.H. et al. Characterization of genes related to the efflux pump and porin in multidrug-resistant Escherichia coli strains isolated from patients with COVID-19 after secondary infection. BMC Microbiol 24, 122 (2024). https://doi.org/10.1186/s12866-024-03283-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12866-024-03283-8

Keywords

BMC Microbiology

ISSN: 1471-2180

Contact us